Results 81 to 90 of about 71,664 (187)

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Supplementary Methods, Figure Legends 1-3, Tables 1A-B from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

, 2010
Supplementary Methods, Figure Legends 1-3, Tables 1A-B from Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast ...
Trung Nguyen (309370), Richard Vandlen (108500), Jay Tibbitts (2157649), Hajime Hiraragi (14983245), Guangmin Li (4245022), Richard H. Scheller (14983248), Elaine Mai (501164), Helga Raab (1593514), Sunil Bhakta (2951277), Jagath R. Junutula (1870864), Kelly M. Flagella (14983233), Debra L. Dugger (14983242), Mark X. Sliwkowski (2948271), Gail D. Lewis Phillips (3076089), Edward Ha (14983239), Kathryn L. Parsons (14983236), Richard A. Graham (14982282), Susan D. Spencer (1564864), Paul Polakis (212576), Reina N. Fuji (4448137)   +19 more
core   +1 more source

A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour‐targeting function

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Site‐specific antibody modification is a useful chemical strategy to elaborate antibody therapeutic function. Conventional lysine‐ or cysteine‐based conjugation methods generate heterogeneous products, while protein engineering approaches are resource‐intensive.
Karolina Krygier, Sandra Szu‐Wei Hwang, Anthony F. Rullo   +2 more
wiley   +1 more source

GUEST EDITORIAL INVITED EDITORIAL

, 2014
perspective A review of the randomized clinical trials of adjuvant trastuzumab in human epidermal growth factor receptor (HER2)–positive breast cancer demonstrates the great benefit of this monoclonal antibody whose potential cardiotoxicity is a ...
Trastuzumab A Cardiologist’s
core  

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Production of Functional Trastuzumab in Phaeodactylum tricornutum: Advancing Microalgae as Next-Generation Sustainable Antibody Biofactories. [PDF]

Plant Biotechnol J
Plant Biotechnology Journal, Volume 24, Issue 10, Page 5405-5407, October 2026.
Toustou C, Salvetti M, Bénard M, Fécourt C, Calbo S, Jouie K, Blanchard F, N'Zué C, Placines C, Badou T, Piton N, Lerouge P, Galas L, Bardor M.   +13 more
europepmc   +2 more sources

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

, 2016
Shannon Puhalla,1 Sharon Wilks,2 Adam M Brufsky,1 Joyce O’Shaughnessy,3 Lee S Schwartzberg,4 Erhan Berrak,5 James Song,5 Linda Vahdat6 1Department of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Department of ...
Puhalla S, O'Shaughnessy J, Wilks S, Brufsky AM, Berrak E, Song J, Vahdat L, Schwartzberg LS   +7 more
core  

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

British Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra, Francesco Niro, Marco Mergiotti, Giovanni Gavatorta, Emilio Hirsch, Alessandra Ghigo   +5 more
wiley   +1 more source

TERT Promoter Mutations Are Preferentially Associated With the ERBB2 G776‐Altered Subtype of HER2‐Mutant NSCLC

Cancer Science, EarlyView.
A two‐stage clinicogenomic analysis identified and independently validated a preferential association between TERT promoter mutations and the ERBB2 G776‐altered subtype of HER2‐mutant NSCLC, highlighting subtype‐specific genomic heterogeneity. ABSTRACT HER2‐mutant non‐small cell lung cancer (NSCLC) comprises molecularly heterogeneous tumors with ...
Akihiro Yoshimura, Juichiro Yoshida, Chieko Takumi, Koichi Takayama   +3 more
wiley   +1 more source

Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer

Cancer Science, EarlyView.
Integrated analysis of 445 bladder cancers showed that HER2 membrane expression and ERBB2 amplification are distinct features. HER2 expression overlapped with NECTIN4 expression, whereas ERBB2 amplification was enriched in the LumU subtype and associated with poor prognosis.
Kensuke Hirosuna, Kazuki Nishimura, Moritoshi Sakamoto, Satoshi Tokushige, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Takeshi Tsutsumi, Ryoichi Maenosono, Takuya Tsujino, Masahiko Ajiro, Haruhito Azuma, Akihide Yoshimi, Kazumasa Komura   +13 more
wiley   +1 more source